MEXAN
 |
|
|
Package(a):
AMPS: 10 x 10 ml x 1,000 mg.
Dosage(a):
To be given concurrently with an oxazaphosphorine cytotoxic agent. Dose depends on mode of administration. See prescribing information for full details.
Prescribing Restrictions:
Package(b):
AMPS: 15 x 4 ml x 400 mg.
Dosage(b):
To be given concurrently with an oxazaphosphorine cytotoxic agent. Dose depends on mode of administration. See prescribing information.
Prescribing Restrictions:
Indications:
Prophylaxis of urothelial toxicity in patients treated with ifosfamide or cyclophoshamide.
Contra-Indications:
Known hypersensitivity to mesna or other thiol compounds. See prescribing information for full details.
Special Precautions:
A morning specimen of urine should be examined for the presence of hematuria and proteinuria, prior to each dose of ifosfamide. If hematuria develops when mesna is administered with ifosfamide, dosage reductions or discontinuation of ifosfamide therapy may be required, depending on the severity of the hematuria. In order to obtain adequate protection, mesna must be administered with each dose of ifosfamide. Pregnancy and breastfeeding. See prescribing information for full details.
Side Effects:
Vomiting, diarrhea and nausea. Allergic symptoms of the skin and mucous membranes, urticarial edema, rare anaphylactoid reactions with fall in blood pressure and tachycardia, transient transaminase elevations. See prescribing information for full details.
Drug Interactions:
N/A
